Camrelizumab plus chemotherapy for triple negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new combination of an immunotherapy drug (camrelizumab) with chemotherapy (nab-paclitaxel) and an allergy medicine (levocetirizine) for people with triple negative breast cancer that has spread or come back. The goal is to see if this combination can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have triple negative breast cancer (meaning tests were negative for estrogen, progesterone, and HER2 receptors) that is either metastatic (spread) or has come back locally and cannot be removed by surgery.
- You have never been treated for this recurrence or spread before.
- You have a tumor that shows a protein called PD-L1 (with a CPS score of at least 1).
- You are able to swallow pills and have an ECOG performance status of 0 or 1, meaning you are fully active or only limited in physically strenuous activity.
- Your blood test results meet certain levels (like adequate white blood cell and platelet counts, and liver and kidney function within limits).
- If you are a woman who can get pregnant, you must have a negative pregnancy test and use effective birth control during and 6 months after treatment.
- Your heart function is normal, with a left ventricular ejection fraction (a measure of pumping strength) of at least 50%.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (camrelizumab and pirfenidone) with chemotherapy to see if it can help people with advanced triple-negative breast cancer. It may offer a new treatment option for those whose cancer has progressed after initial treatment.
This Phase 2 trial tests adding camrelizumab (an immune therapy) to standard chemotherapy before surgery for people with triple-negative breast cancer that has not spread. It aims to improve how much the tumor shrinks before and around the time of surgery.
This trial tests whether adding an immunotherapy drug (camrelizumab) to standard chemotherapy before surgery can improve outcomes for women with early-stage triple-negative breast cancer. The treatment is given before surgery to shrink tumors and may help prevent the cancer from coming back.
This trial tests a combination of an immunotherapy drug (PD-L1 antibody) along with a low-dose oral chemotherapy ('metronomic') called VEX for people with advanced triple-negative breast cancer. The goal is to see if this combination is safe and effective in controlling the cancer.
This trial studies whether adding camrelizumab (an immunotherapy drug) to radiation can improve outcomes and be safe for people with early triple-negative breast cancer. It is designed for specific early-stage cases after breast surgery, using tumor and blood tests to match the cancer’s features.
This trial tests whether giving the immunotherapy drug camrelizumab along with chemotherapy and radiation before surgery can help shrink early-stage triple-negative breast cancer tumors. It aims to improve treatment outcomes for this aggressive but curable cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.